【石药集团盘中股价变动，附属公司药物获突破性治疗认定】石药集团盘中涨近 3%，截至发稿，股价上涨 1.31%，现报 4.65 港元，成交额 5012.46 万港元。近日，石药集团公布，其附属公司巨石生物制药有限公司开发的 SYS6010 获中国国家药品监督管理局授予突破性治疗认定，拟定适应症为单药用于经 EGFR-TKI 和含铂化疗治疗失败的 EGFR 突变阳性晚期非小细胞肺癌。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.